Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Commentary: Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases.

Vellayappan B, Foote M, Redmond KJ, Chao ST, Lo SS.

Neurosurgery. 2019 Jun 5. pii: nyz189. doi: 10.1093/neuros/nyz189. [Epub ahead of print] No abstract available.

PMID:
31165871
2.

The importance of staying connected: Mediating and moderating effects of social group memberships on psychological well-being after brain tumor.

Cubis L, Ownsworth T, Pinkham MB, Foote M, Legg M, Chambers S.

Psychooncology. 2019 May 21. doi: 10.1002/pon.5125. [Epub ahead of print]

PMID:
31115102
3.

Unseen Trauma-Our Responsibility to Discover.

Foote MB.

JAMA Intern Med. 2019 Mar 25. doi: 10.1001/jamainternmed.2019.0234. [Epub ahead of print] No abstract available.

PMID:
30907947
4.

Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy.

Liu HY, Milne R, Lock G, Panizza BJ, Bernard A, Foote M, McGrath M, Brown E, Gandhi M, Porceddu SV.

Oral Oncol. 2019 Jan;88:153-159. doi: 10.1016/j.oraloncology.2018.11.033. Epub 2018 Dec 5.

PMID:
30616786
5.

Proceedings of the 2018 next-generation Gamma Knife research meeting.

Chiang VL, Chao ST, Tuleasca C, Foote MC, Lee CC, Mathieu D, Soliman H, Sahgal A.

J Neurosurg. 2018 Dec 1;129(Suppl1):5-9. doi: 10.3171/2018.7.GKS181206.

PMID:
30544302
6.

Commentary: Stereotactic Body Radiotherapy for Spinal Metastases at the Extreme Ends of the Spine: Imaging-Based Outcomes for Cervical and Sacral Metastases.

Vellayappan B, Tan D, Foote M, Redmond KJ, Lo SS.

Neurosurgery. 2018 Oct 8. doi: 10.1093/neuros/nyy428. [Epub ahead of print] No abstract available.

PMID:
30295828
7.

Radiological Kinetics of Brain Metastases and Clinical Implications for Patients Treated With Stereotactic Radiosurgery.

Nicholls LW, Pinkham MB, Bernard A, Lusk R, Watkins T, Hall B, Olson S, Foote MC.

Clin Oncol (R Coll Radiol). 2019 Jan;31(1):34-40. doi: 10.1016/j.clon.2018.09.005. Epub 2018 Sep 29.

PMID:
30279038
8.

An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes.

Joseph SR, Gaffney D, Barry R, Hu L, Banushi B, Wells JW, Lambie D, Strutton G, Porceddu SV, Burmeister B, Leggatt GR, Schaider H, Dolcetti R, Frazer IH, Saunders NA, Foote M, Soyer HP, Simpson F.

J Invest Dermatol. 2019 Jan;139(1):213-223. doi: 10.1016/j.jid.2018.06.190. Epub 2018 Aug 2.

9.

The evolution and rise of stereotactic body radiotherapy (SBRT) for spinal metastases.

Vellayappan BA, Chao ST, Foote M, Guckenberger M, Redmond KJ, Chang EL, Mayr NA, Sahgal A, Lo SS.

Expert Rev Anticancer Ther. 2018 Sep;18(9):887-900. doi: 10.1080/14737140.2018.1493381. Epub 2018 Jul 3. Review.

PMID:
29940802
10.

Pacing of Paleozoic macroevolutionary rates by Milankovitch grand cycles.

Crampton JS, Meyers SR, Cooper RA, Sadler PM, Foote M, Harte D.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):5686-5691. doi: 10.1073/pnas.1714342115. Epub 2018 May 14.

11.

Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report.

Laufer I, Lo SS, Chang EL, Sheehan J, Guckenberger M, Sohn MJ, Ryu S, Foote M, Muacevic A, Soltys SG, Chao S, Myrehaug S, Gerszten PC, Lis E, Maralani P, Bilsky M, Fisher C, Rhines L, Verlaan JJ, Schiff D, Fehlings MG, Ma L, Chang S, Parulekar WR, Vogelbaum MA, Sahgal A.

Neuro Oncol. 2018 Aug 2;20(9):1215-1224. doi: 10.1093/neuonc/noy047.

PMID:
29590465
12.

Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study.

Read TA, Smith A, Thomas J, David M, Foote M, Wagels M, Barbour A, Smithers BM.

J Surg Oncol. 2018 Mar;117(4):579-587. doi: 10.1002/jso.24921. Epub 2018 Mar 12.

PMID:
29529343
13.

Diversity-dependent evolutionary rates in early Palaeozoic zooplankton.

Foote M, Cooper RA, Crampton JS, Sadler PM.

Proc Biol Sci. 2018 Feb 28;285(1873). pii: 20180122. doi: 10.1098/rspb.2018.0122.

14.

In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely.

Pinkham MB, Sahgal A, Pullar AP, Foote MC.

BMC Cancer. 2017 Nov 15;17(1):768. doi: 10.1186/s12885-017-3672-z.

15.

Using "Mystery Patient" Drills to Assess Hospital Ebola Preparedness in New York City, 2014-2015.

Foote M, Daver R, Quinn C.

Health Secur. 2017 Sep/Oct;15(5):500-508. doi: 10.1089/hs.2016.0130. Epub 2017 Sep 22.

PMID:
28937795
16.

Assessment of Hospital Emergency Department Response to Potentially Infectious Diseases Using Unannounced Mystery Patient Drills - New York City, 2016.

Foote MMK, Styles TS, Quinn CL.

MMWR Morb Mortal Wkly Rep. 2017 Sep 15;66(36):945-949. doi: 10.15585/mmwr.mm6636a2.

17.

Postoperative stereotactic radiosurgery for limited brain metastases: are we ready for prime time?

Lo SS, Brown PD, Foote M, Chao ST, Chang EL, Sahgal A.

Expert Rev Anticancer Ther. 2017 Sep;17(9):775-777. doi: 10.1080/14737140.2017.1358090. Epub 2017 Jul 24. No abstract available.

PMID:
28737065
18.

Consider Adjuvant Intensity Modulated Radiation Therapy to the Lymph Node Basin, Especially If the Melanoma Is BRAF Wild Type.

Foote M.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):15. doi: 10.1016/j.ijrobp.2016.12.029. No abstract available.

PMID:
28586954
19.

How electronic health records can unmask the hidden value of PAs.

Ogunfiditimi F, Sherry SP, Foote M, Christie SL, Shock LP, Cawley J, Browne A; American Academy of PAs Fee for Value Task Force.

JAAPA. 2017 Jun;30(6):1-3. doi: 10.1097/01.JAA.0000516345.50761.e3.

PMID:
28538436
20.

Vector-model-supported optimization in volumetric-modulated arc stereotactic radiotherapy planning for brain metastasis.

Liu ESF, Wu VWC, Harris B, Foote M, Lehman M, Chan LWC.

Med Dosim. 2017 Summer;42(2):85-89. doi: 10.1016/j.meddos.2017.01.002. Epub 2017 Mar 18.

PMID:
28318935
21.

Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation.

Huo M, Sahgal A, Pryor D, Redmond K, Lo S, Foote M.

Surg Neurol Int. 2017 Feb 20;8:30. doi: 10.4103/2152-7806.200581. eCollection 2017. Review.

22.

Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.

Porceddu SV, Milne R, Brown E, Bernard A, Rahbari R, Cartmill B, Foote M, McGrath M, Coward J, Panizza B.

Oral Oncol. 2017 Mar;66:81-86. doi: 10.1016/j.oraloncology.2017.01.002. Epub 2017 Jan 21.

PMID:
28249652
23.

Risk Profiles for Sensorineural Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin-based Chemoradiation.

Shorter P, Harden F, Owen R, Panizza B, Burmeister B, Sommerville J, Mengersen K, Foote M.

J Med Imaging Radiat Sci. 2017 Mar;48(1):61-67. doi: 10.1016/j.jmir.2016.11.005. Epub 2016 Dec 26.

PMID:
31047212
24.

Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases.

Chang JH, Gandhidasan S, Finnigan R, Whalley D, Nair R, Herschtal A, Eade T, Kneebone A, Ruben J, Foote M, Siva S.

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e119-e125. doi: 10.1016/j.clon.2017.02.004. Epub 2017 Feb 23.

PMID:
28237218
25.

Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma.

Foote M, Read T, Thomas J, Wagels M, Burmeister B, Smithers BM.

J Surg Oncol. 2017 Jun;115(7):891-897. doi: 10.1002/jso.24580. Epub 2017 Feb 23.

26.

A multinational report of technical factors on stereotactic body radiotherapy for oligometastases.

Redmond KJ, Lo SS, Dagan R, Poon I, Foote MC, Erler D, Lee Y, Lohr F, Biswas T, Ricardi U, Sahgal A.

Future Oncol. 2017 May;13(12):1081-1089. doi: 10.2217/fon-2016-0479. Epub 2017 Feb 3.

PMID:
28152619
27.
28.

Radiotherapy in Glioblastoma: the Past, the Present and the Future.

Gzell C, Back M, Wheeler H, Bailey D, Foote M.

Clin Oncol (R Coll Radiol). 2017 Jan;29(1):15-25. doi: 10.1016/j.clon.2016.09.015. Epub 2016 Oct 13. Review.

PMID:
27743773
29.

Conformal orbit sparing radiation therapy: a treatment option for advanced skin cancer of the parotid and ear region.

Foley H, Hopley S, Brown E, Bernard A, Foote M.

J Med Radiat Sci. 2016 Sep;63(3):186-94. doi: 10.1002/jmrs.161. Epub 2016 Mar 19.

30.

Diagnostic potential of tumor DNA from ovarian cyst fluid.

Wang Y, Sundfeldt K, Mateoiu C, Shih IeM, Kurman RJ, Schaefer J, Silliman N, Kinde I, Springer S, Foote M, Kristjansdottir B, James N, Kinzler KW, Papadopoulos N, Diaz LA, Vogelstein B.

Elife. 2016 Jul 15;5. pii: e15175. doi: 10.7554/eLife.15175.

31.

What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Foote MM, Careaga M, Berman RF.

Clin Neuropsychol. 2016 Aug;30(6):960-72. doi: 10.1080/13854046.2016.1158254. Epub 2016 Jun 29. Review.

32.

Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Motor Dysfunction Modeled in Mice.

Foote M, Arque G, Berman RF, Santos M.

Cerebellum. 2016 Oct;15(5):611-22. doi: 10.1007/s12311-016-0797-6. Review.

33.

The Role of Postoperative Radiotherapy for Large Nerve Perineural Spread of Cancer of the Head and Neck.

Gorayski P, Foote M, Porceddu S, Poulsen M.

J Neurol Surg B Skull Base. 2016 Apr;77(2):173-81. doi: 10.1055/s-0036-1571839. Epub 2016 Feb 26. Review.

34.

Evaluation of accuracy and reproducibility of a relocatable maxillary fixation system for fractionated intracranial stereotactic radiation therapy.

Russo M, Owen R, Bernard A, Moutrie V, Foote M.

J Med Radiat Sci. 2016 Mar;63(1):41-7. doi: 10.1002/jmrs.142. Epub 2015 Sep 22.

35.

Technical know-how in stereotactic ablative radiotherapy (SABR).

Lo SS, Foote M, Siva S, Slotman BJ, Teh BS, Guckenberger M, Tan D, Mayr NA, Sahgal A.

J Med Radiat Sci. 2016 Mar;63(1):5-8. doi: 10.1002/jmrs.163. Epub 2016 Mar 3.

36.

The High Burden of Cancer Among American Indians/Alaska Natives in Wisconsin.

Foote M, Strickland R, Lucas-Pipkorn S, Williamson A, Lamers L.

WMJ. 2016 Feb;115(1):11-6.

37.

A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up.

Dagan R, Lo SS, Redmond KJ, Poon I, Foote MC, Lohr F, Ricardi U, Sahgal A.

Acta Oncol. 2016 May;55(5):633-7. doi: 10.3109/0284186X.2015.1118659. Epub 2016 Apr 4.

PMID:
27046290
38.

Diabetes mellitus and extrapulmonary tuberculosis: site distribution and risk of mortality.

Magee MJ, Foote M, Ray SM, Gandhi NR, Kempker RR.

Epidemiol Infect. 2016 Jul;144(10):2209-16. doi: 10.1017/S0950268816000364. Epub 2016 Mar 1.

39.

Inter- and intra-fraction motion in stereotactic body radiotherapy for spinal and paraspinal tumours using cone-beam CT and positional correction in six degrees of freedom.

Finnigan R, Lamprecht B, Barry T, Jones K, Boyd J, Pullar A, Burmeister B, Foote M.

J Med Imaging Radiat Oncol. 2016 Feb;60(1):112-8. doi: 10.1111/1754-9485.12353. Epub 2015 Sep 7.

PMID:
26813044
40.

Greenhouse-icehouse transition in the Late Ordovician marks a step change in extinction regime in the marine plankton.

Crampton JS, Cooper RA, Sadler PM, Foote M.

Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1498-503. doi: 10.1073/pnas.1519092113. Epub 2016 Jan 25.

41.

Stereotactic radiosurgery alone for limited brain metastases: are we ready for prime time?

Lo SS, Redmond KJ, Chang EL, Foote M, Knisely JP, Sahgal A.

CNS Oncol. 2016;5(1):1-4. doi: 10.2217/cns.15.39. Epub 2015 Dec 18. No abstract available.

42.

Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group.

Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn MJ, Ryu S, Foote M, Lo SS, Muacevic A, Soltys SG, Chao S, Gerszten P, Lis E, Yu E, Bilsky M, Fisher C, Schiff D, Fehlings MG, Ma L, Chang S, Chow E, Parelukar WR, Vogelbaum MA, Sahgal A.

Lancet Oncol. 2015 Dec;16(16):e595-603. doi: 10.1016/S1470-2045(15)00166-7. Review.

PMID:
26678212
43.

David M. Raup, 1933-2015.

Foote M.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15002-3. doi: 10.1073/pnas.1521181112. Epub 2015 Nov 24. No abstract available.

44.

Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery.

Tian X, Lara H, Wagner KT, Saripalli S, Hyder SN, Foote M, Sethi M, Wang E, Caster JM, Zhang L, Wang AZ.

Nanoscale. 2015 Dec 21;7(47):20211-9. doi: 10.1039/c5nr05869d. Epub 2015 Nov 17.

45.

Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy.

Croker J, Chua B, Bernard A, Allon M, Foote M.

Clin Exp Metastasis. 2016 Feb;33(2):125-32. doi: 10.1007/s10585-015-9762-x. Epub 2015 Oct 19.

PMID:
26482476
46.

Single versus multiple session stereotactic body radiotherapy for spinal metastasis: the risk-benefit ratio.

Redmond KJ, Sahgal A, Foote M, Knisely J, Gerszten PC, Chao ST, Suh JH, Sloan AE, Chang EL, Machtay M, Lo SS.

Future Oncol. 2015;11(17):2405-15. doi: 10.2217/fon.15.160. Epub 2015 Sep 15. Review. Erratum in: Future Oncol. 2015;11(23):3220.

PMID:
26369361
48.

The development of stereotactic body radiotherapy in the past decade: a global perspective.

Lo SS, Slotman BJ, Lock M, Nagata Y, Guckenberger M, Siva S, Foote M, Tan D, Teh BS, Mayr NA, Chang EL, Timmerman RD, Sahgal A.

Future Oncol. 2015 Oct;11(19):2721-2733. doi: 10.2217/fon.15.220. Epub 2015 Sep 4.

PMID:
26338676
49.

The Many Faces of the Hospital.

Foote MB.

Acad Med. 2015 Sep;90(9):1198. doi: 10.1097/ACM.0000000000000825. No abstract available.

PMID:
26307930
50.

A systematic review of non-surgical treatments for lentigo maligna.

Read T, Noonan C, David M, Wagels M, Foote M, Schaider H, Soyer HP, Smithers BM.

J Eur Acad Dermatol Venereol. 2016 May;30(5):748-53. doi: 10.1111/jdv.13252. Epub 2015 Aug 24. Review.

PMID:
26299846

Supplemental Content

Support Center